Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. AAPL
2. PLTR
3. DOX
4. VRTX
5. CHKP
6. CRWD
7. ON
8. INSP
9. HNGE
10. AMD

Go back to Fennec Pharmaceuticals (FENC) Misses Q2 EPS by 6c

Fennec Pharmaceuticals Announces Second Quarter 2022 Financial Results and Provides Business Update

August 12, 2022 6:59 AM EDT

~ PEDMARKTM FDA Prescription Drug User Fee Act (PDUFA) Target Action Date Set for September 23, 2022 ~

~ Commercial Team Built Out In Anticipation of U.S. Launch of PEDMARKTM ~

~ Recently Announced Up to $45 Million in Funding from Petrichor to Support the Potential U.S. Commercialization of PEDMARKTM ~

RESEARCH TRIANGLE PARK, N.C., Aug. 12, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a... More